Oral Mucositis (OM) - Epidemiology Forecast to 2027

  • ID: 4382500
  • Report
  • 60 pages
  • DelveInsight
1 of 3
‘Oral Mucositis (OM) - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Oral Mucositis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
  • China
Study Period: 2016-2027

Oral Mucositis Epidemiology

The Oral Mucositis (OM) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every G8 countries. The epidemiology data for Oral Mucositis are studied through all possible division to give a better understanding about the Disease scenario in G8 countries. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Oral Mucositis Epidemiology Segmentation

The Oral Mucositis (OM) epidemiology division provide the insights about historical and current patient pool and forecasted trend for G8 countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total Diagnosed Incident cases, Grade-specific cases, Risk Factor Associated cases), scenario of Oral Mucositis (OM) in the G8 countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) Japan and China from 2016-2027.

According to this research, total diagnosed incident population of Oral Mucositis (OM) in G8 countries was found to be 5,333,193 in 2016.

Report Scope
  • The report covers detailed overview of Oral Mucositis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Oral Mucositis in G8 countries covering the United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the G8 countries with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by Grade-specific i.e., Grade I (Mild), Grade II (Moderate), Grade III (Severe) and Grade IV (Life Threatening) Oral Mucositis in G8 countries
  • The report also provides the risk factor associated diagnosed incident population of Oral Mucositis (Head & Neck Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Esophageal Cancer, Malignant Lymphoma, Leukemia, Prostate Cancer, Pancreatic Cancer, Bladder Cancer, Multiple Myeloma, other cancers and Hematopoietic Stem Cell Transplantation)
Key strengths

- 10 Year Forecast of Oral Mucositis epidemiology
  • G8 countries Coverage
  • Total Diagnosed Incident Cases of OM
  • Diagnosed Incident Cases according to segmentation: Grade-specific Diagnosed Incidence i.e. Grade I (Mild), Grade II (Moderate), Grade III (Severe) and Grade IV (Life Threatening)
  • Risk factor Associated Diagnosed Incident cases of OM
Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Key Insights

2. The Report contains:

3. Oral Mucositis Market: Overview at a Glance
3.1. Market Share Distribution of OM in 2017
3.2. Market Share Distribution of OM in 2027

4. Oral Mucositis (OM): Disease Background and Overview
4.1. Introduction
4.2. Symptoms
4.3. Etiology
4.4. Risk Factors of Oral Mucositis
4.5. Pathophysiology
4.6. Diagnosis of Oral Mucositis
4.7. Clinical Oral Mucositis Assessment Scales
4.8. World Health Organization (WHO) scale for oral mucositis
4.9. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
4.10. References

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Diagnosed Incident Cases of Oral Mucositis in G8 Countries

6. Country-Specific Epidemiology of Oral Mucositis
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Diagnosed Incident Population of Oral Mucositis in the United States
6.1.3. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in the United States
6.1.4. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in the United States
6.2. EU5
6.2.1. Assumptions and Rationale
6.3. Germany
6.3.1. Diagnosed Incident Population of Oral Mucositis in Germany
6.3.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Germany
6.3.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in Germany
6.4. France
6.4.1. Diagnosed Incident Population of Oral Mucositis in France
6.4.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in France
6.4.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in France
6.5. Italy
6.5.1. Diagnosed Incident Population of Oral Mucositis in Italy
6.5.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Italy
6.5.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in Italy
6.6. Spain
6.6.1. Diagnosed Incident Population of Oral Mucositis in Spain
6.6.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Spain
6.6.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in Spain
6.7. United Kingdom
6.7.1. Diagnosed Incident Population of Oral Mucositis in the United Kingdom
6.7.2. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in the United Kingdom
6.7.3. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in the United Kingdom
6.8. Japan
6.8.1. Assumptions and Rationale
6.8.2. Diagnosed Incident Population of Oral Mucositis in Japan
6.8.3. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in Japan
6.8.4. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in Japan
6.9. China
6.9.1. Assumptions and Rationale
6.9.2. Diagnosed Incident Population of Oral Mucositis in China
6.9.3. Grade-Specific Diagnosed Incident Cases of Oral Mucositis in China
6.9.4. Risk Factor Associated Diagnosed Incident Cases of Oral Mucositis in China

7. Unmet Needs

8. Market Drivers

9. Market Barriers

10. The Publisher's Capabilities

11. Appendix
11.1. Report Methodology

12. Disclaimer

13. About the Publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll